Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) - Total Liabilities

Latest as of September 2025: CN¥877.24 Million CNY ≈ $128.37 Million USD

Based on the latest financial reports, Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) has total liabilities worth CN¥877.24 Million CNY (≈ $128.37 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Cheng Du Sheng Nuo Biotec Co. Ltd. A - Total Liabilities Trend (2017–2024)

This chart illustrates how Cheng Du Sheng Nuo Biotec Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Cheng Du Sheng Nuo Biotec Co. Ltd. A's working capital to evaluate short-term liquidity relative to the company's equity base.

Cheng Du Sheng Nuo Biotec Co. Ltd. A Competitors by Total Liabilities

The table below lists competitors of Cheng Du Sheng Nuo Biotec Co. Ltd. A ranked by their total liabilities.

Company Country Total Liabilities
Pharmicell
KO:005690
Korea ₩19.60 Billion
Fireweed Zinc Ltd
V:FWZ
Canada CA$15.54 Million
Shijihengtong Technology Co. Ltd. A
SHE:301428
China CN¥1.22 Billion
Jiangsu Fasten Co Ltd
SHE:000890
China CN¥784.10 Million
Henan Huaying Agricultural Development Co Ltd
SHE:002321
China CN¥2.51 Billion
Tekla Life Sciences Investors
NYSE:HQL
USA $1.73 Million
Yantai Ishikawa Sealing Technology Co.Ltd.
SHE:301020
China CN¥239.17 Million
Bridgewater Bancshares Inc
NASDAQ:BWB
USA $4.81 Billion

Liability Composition Analysis (2017–2024)

This chart breaks down Cheng Du Sheng Nuo Biotec Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.46 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.85 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.46 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cheng Du Sheng Nuo Biotec Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cheng Du Sheng Nuo Biotec Co. Ltd. A (2017–2024)

The table below shows the annual total liabilities of Cheng Du Sheng Nuo Biotec Co. Ltd. A from 2017 to 2024.

Year Total Liabilities Change
2024-12-31 CN¥729.58 Million
≈ $106.76 Million
+67.48%
2023-12-31 CN¥435.63 Million
≈ $63.75 Million
+54.88%
2022-12-31 CN¥281.27 Million
≈ $41.16 Million
+64.03%
2021-12-31 CN¥171.48 Million
≈ $25.09 Million
+10.34%
2020-12-31 CN¥155.41 Million
≈ $22.74 Million
+9.09%
2019-12-31 CN¥142.46 Million
≈ $20.85 Million
-5.59%
2018-12-31 CN¥150.90 Million
≈ $22.08 Million
+41.74%
2017-12-31 CN¥106.46 Million
≈ $15.58 Million
--

About Cheng Du Sheng Nuo Biotec Co. Ltd. A

SHG:688117 China Drug Manufacturers - Specialty & Generic
Market Cap
$546.28 Million
CN¥3.73 Billion CNY
Market Cap Rank
#11908 Global
#3451 in China
Share Price
CN¥23.72
Change (1 day)
+2.60%
52-Week Range
CN¥21.44 - CN¥46.10
All Time High
CN¥48.78
About

ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide,… Read more